Sort   by:  
 Page size 
ProteomicsMEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas
Combining multiple therapeutic strategies in NRAS/BRAF mutant melanoma – namely MEK/BRAF kinase inhibitors, immune checkpoint inhibitors, and targeted immunotherapies – may offer an improved survival benefit by overcoming limitations associated with any individual therapy. Still, optimal combination...
ORGANISM(S): Homo sapiens (Human) 
2023-03-11 | PXD029860 | Pride
Hla Mhc Immunopeptidomics Antigen presentation 
ProteomicsMEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas - targeted data
Combining multiple therapeutic strategies in NRAS/BRAF mutant melanoma – namely MEK/BRAF kinase inhibitors, immune checkpoint inhibitors, and targeted immunotherapies – may offer an improved survival benefit by overcoming limitations associated with any individual therapy. Still, optimal combination...
ORGANISM(S): Homo sapiens (Human) 
2023-03-11 | PXD029884 | Pride
Hla Targeted Mhc Immunopeptidomics Antigen presentation Surequant 
Sort   by:  
 Page size